These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20961278)

  • 1. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
    Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
    Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
    J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
    Charpentier C; Malet I; Andre-Garnier E; Storto A; Bocket L; Amiel C; Morand-Joubert L; Tumiotto C; Nguyen T; Maillard A; Rodallec A; Leoz M; Montes B; Schneider V; Plantier JC; Dina J; Pallier C; Mirand A; Roussel C; Signori-Schmuck A; Raymond S; Calvez V; Delaugerre C; Marcelin AG; Descamps D
    J Antimicrob Chemother; 2018 Apr; 73(4):1039-1044. PubMed ID: 29342281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
    Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
    J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
    Llácer Delicado T; Torrecilla E; Holguín Á
    J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
    Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
    Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
    Charpentier C; Descamps D
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.
    Nouhin J; Donchai T; Hoang KT; Ken S; Kamkorn J; Tran T; Ayouba A; Peeters M; Chaix ML; Lien TX; Nerrienet E; Ngo-Giang-Huong N
    Infect Genet Evol; 2011 Jan; 11(1):38-43. PubMed ID: 21094281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
    Rhee SY; Liu TF; Kiuchi M; Zioni R; Gifford RJ; Holmes SP; Shafer RW
    Retrovirology; 2008 Aug; 5():74. PubMed ID: 18687142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of raltegravir resistance during therapy.
    Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
    J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
    Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
    Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 integrase inhibitor resistance and its clinical implications.
    Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
    J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.